Antibody-based cancer immunotherapy

Available On Demand

Your details

Email *

* Required

First Name *

* Required

Last Name *

* Required

Company *

* Required

City *

* Required

State *

* Required

Zip Code *

* Required

Country *

* Required

I would like to receive a one-time e-mail from Eppendorf after this webinar with a link to this recording and related contents. *

YesNo

Yes, please email me from time to time about Springer Nature programs, products or services (tick to consent). You can withdraw consent at any time by clicking on the unsubscribe link at the bottom of these emails. * Required

I am aware of Eppendorf's Privacy Policy. Click here to read it. * Required

I express consent that my personal data can be stored and used by Eppendorf Group for advertising or marketing purposes, e.g. for providing information and offers concerning the goods and services of Eppendorf by email, mail or phone. This consent is voluntary and can be withdrawn, completely or in part, at any time by contacting privacy@eppendorf.com. * Required

By registering here, you agree that we can contact you to provide you with information about this webcast and your registration details will be seen by Springer Nature and the sponsor. We will not otherwise disclose your personal data to anyone else unless we have your permission as detailed in our Privacy Policy. Terms and conditions can be viewed here. *

I Agree * Required

Our registration process uses cookies. By submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Presented by:

Produced with support from:

Antibody-based cancer immunotherapy

Available On Demand

Overview

If you’ve already registered, please click here to log in to the webcast.

Cancer immunotherapy, including but not limited to immune-checkpoint inhibitors, has revolutionized cancer treatment in the last decade and there is a continuous expansion of immuno-oncology pipeline drugs and active clinical trials. In this scenario, antibody development for cancer therapy is a major priority for the immune-oncology field. For this webcast, we have brought together experts to discuss approaches to identify novel targets of interest and to develop antibodies and therapeutic proteins for cancer immunotherapy, with a focus on manufacturing, antibody engineering and optimization.

This webcast has been produced by Nature Communications, who retains sole responsibility for content. About this content.

Presenters

Dr. Christian Klein

Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery
Roche Innovation Center Zurich
View Biography

Professor Sophia Karagiannis

Professor of Translational Cancer Immunology and Immunotherapy
King's College London
View Biography

Ildiko Gyory

Associate Editor
Nature Communications
View Biography

Luca Danelli

Senior Editor
Nature Communications
View Biography